Integrating "Physical Intelligence" to Accelerate Next-Gen Drug Validation and Bio-AX Revolution SANTA CLARA, CA, ...

AI could review data sets to assist clinical scientists ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

Some say we’ve entered a new age of AI-enabled scientific discovery. But human insight and creativity still can’t be ...

The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion ...

LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Generative AI is transforming the biotechnology world at record speed. From designing drug compounds in silico to advancing precision medicine through deep genomic and clinical analysis, AI is ...

Merck & Co. Inc. MRK on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence ...